Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Advanced/Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

pay.thelady61 shared this article with you from Inoreader Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Advanced/Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Via ClinicalTrials.gov: HEAD AND NECK | Open Studies | updated in the last 14 days Condition:   Advanced/Metastatic HER2 Negative Gastric/Gastroesophageal Junction Adenocarcinoma Interventions:   Biological: Pembrolizumab;   Biological: Lenvatinib;   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: Leucovorin;   Drug: 5-FU Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc. Not yet recruiting View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.